Effectiveness and Safety of Different Antithrombotic Therapy for the Treatment of Ventricular Thrombus
NCT ID: NCT05006677
Last Updated: 2023-03-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
480 participants
OBSERVATIONAL
2021-08-04
2023-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Direct Oral Anticoagulants for the Treatment of Cerebral Venous Thrombosis
NCT04660747
The Safety of Non-vitamin K Oral Anticoagulants Compared to Warfarin Early After Cardiac Surgery
NCT05006287
Comparative Study of Oral Anticoagulation in Left Ventricular Thrombi
NCT03926780
Cohort of Patients With Left Ventricular Thrombus: Management and Outcomes in the Direct Oral Anticoagulants Era
NCT05028777
Safety and Efficacy of Edoxaban and Rivaroxaban to Cerebral Venous Thrombosis in Chinese Patients
NCT06947707
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
non-vitamin K antagonist oral anticoagulants (NOACs)
non-vitamin K antagonist oral anticoagulants (NOACs)
Collecting information of patients with VT who received NOACs
vitamin K antagonists (VKAs)
vitamin K antagonists (VKAs)
Collecting information of patients with VT who received VKAs
antiplatelet agents
antiplatelet agents
Collecting information of patients with VT who received antiplatelet agents
non-antithrombotic therapy
non-antithrombotic therapy
Collecting information of patients with VT without any antithrombotic therapy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
non-vitamin K antagonist oral anticoagulants (NOACs)
Collecting information of patients with VT who received NOACs
vitamin K antagonists (VKAs)
Collecting information of patients with VT who received VKAs
antiplatelet agents
Collecting information of patients with VT who received antiplatelet agents
non-antithrombotic therapy
Collecting information of patients with VT without any antithrombotic therapy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The VT should be found newly within 3 months;
* The observational phase should last until the time that patients who had achieved thrombus resolution. The following up period after the phase ended should continue for at least 3 months.
Exclusion Criteria
* Individuals received the thrombectomy therapy, ventricular aneurysm resection or heart transplantation within 6 weeks since the VT was found in the first time;
* Had a long history of VT more than three months.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
China National Center for Cardiovascular Diseases
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Qing Yang
Beijing, , China
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Gianstefani S, Douiri A, Delithanasis I, Rogers T, Sen A, Kalra S, Charangwa L, Reiken J, Monaghan M, MacCarthy P. Incidence and predictors of early left ventricular thrombus after ST-elevation myocardial infarction in the contemporary era of primary percutaneous coronary intervention. Am J Cardiol. 2014 Apr 1;113(7):1111-6. doi: 10.1016/j.amjcard.2013.12.015. Epub 2014 Jan 14.
Turpie AG, Robinson JG, Doyle DJ, Mulji AS, Mishkel GJ, Sealey BJ, Cairns JA, Skingley L, Hirsh J, Gent M. Comparison of high-dose with low-dose subcutaneous heparin to prevent left ventricular mural thrombosis in patients with acute transmural anterior myocardial infarction. N Engl J Med. 1989 Feb 9;320(6):352-7. doi: 10.1056/NEJM198902093200604.
Abdelnaby M, Almaghraby A, Abdelkarim O, Saleh Y, Hammad B, Badran H. The role of rivaroxaban in left ventricular thrombi. Anatol J Cardiol. 2019 Jan;21(1):47-50. doi: 10.14744/AnatolJCardiol.2018.48313. No abstract available.
Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC); Steg PG, James SK, Atar D, Badano LP, Blomstrom-Lundqvist C, Borger MA, Di Mario C, Dickstein K, Ducrocq G, Fernandez-Aviles F, Gershlick AH, Giannuzzi P, Halvorsen S, Huber K, Juni P, Kastrati A, Knuuti J, Lenzen MJ, Mahaffey KW, Valgimigli M, van 't Hof A, Widimsky P, Zahger D. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012 Oct;33(20):2569-619. doi: 10.1093/eurheartj/ehs215. Epub 2012 Aug 24. No abstract available.
He J, Ge H, Dong JX, Zhang W, Kong LC, Qiao ZQ, Zheng Y, Ding S, Wan F, Shen L, Wang W, Gu ZC, Yang F, Li Z, Pu J. Rationale and design of a prospective multi-center randomized trial of EARLY treatment by rivaroxaban versus warfarin in ST-segment elevation MYOcardial infarction with Left Ventricular Thrombus (EARLY-MYO-LVT trial). Ann Transl Med. 2020 Mar;8(6):392. doi: 10.21037/atm.2020.02.117.
Guddeti RR, Anwar M, Walters RW, Apala D, Pajjuru V, Kousa O, Gujjula NR, Alla VM. Treatment of Left Ventricular Thrombus With Direct Oral Anticoagulants: A Retrospective Observational Study. Am J Med. 2020 Dec;133(12):1488-1491. doi: 10.1016/j.amjmed.2020.05.025. Epub 2020 Jun 27.
Yang Q, Liang Y, Quan X, Lang X, Gao D. Characteristics of Novel Anticoagulants versus Vitamin K Antagonists in the Ventricular Mural Thrombus. Rev Cardiovasc Med. 2023 Mar 2;24(3):74. doi: 10.31083/j.rcm2403074. eCollection 2023 Mar.
Yang Q, Quan X, Lang X, Liang Y. Predicting Thromboembolism in Hospitalized Patients with Ventricular Thrombus. Rev Cardiovasc Med. 2022 Nov 30;23(12):390. doi: 10.31083/j.rcm2312390. eCollection 2022 Dec.
Yang Q, Lang X, Quan X, Gong Z, Liang Y. Different Oral Antithrombotic Therapy for the Treatment of Ventricular Thrombus: An Observational Study from 2010 to 2019. Int J Clin Pract. 2022 Feb 24;2022:7400860. doi: 10.1155/2022/7400860. eCollection 2022.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2021-TR
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.